Rapid Screening For Elevated Bile Acids Using Whole Blood

Project ID: D2022-12 ­Chronic liver disease (CLD) exerts a huge economic burden causing 3.5% of deaths worldwide mainly due to poor early diagnosis of the disease. COVID-19 has also contributed a moderate impact causing further burden to CLD diagn…

Chronic liver disease (CLD) exerts a huge economic burden causing 3.5% of deaths worldwide mainly due to poor early diagnosis of the disease. COVID-19 has also contributed a moderate impact causing further burden to CLD diagnosis. Cholemia and cholestasis are pathological conditions related to liver disorders with excess of bile acids in the blood. One unique feature of cholestasis is jaundice with abnormally elevated levels of bilirubin as well as bile acids in the blood, whereas in cholemia, only bile acids but not bilirubin is elevated in the blood. While jaundice has been extensively studied and have well-established diagnosis, cholemia is largely asymptomatic in nature with no existing simple and routine methodology for the diagnosis. Currently, the gold standard for liver function test is an assay of serum alanine transaminase (ALT; aka SGPT) and measuring serum bilirubin if sera appear yellowish in color. These tests typically require symptoms to be present (e.g., jaundice), which can limit early detection and treatment options for asymptomatic cholemia. As a result, commonly used liver function tests (serum ALT) do not actually measure liver function, but rather, merely detect acute but not chronic liver injury. There is a need for highly accurate, low-cost, and sensitive test for cholemia, a clinical condition in which blood bile acid levels increase by 10-20 fold without any increase in serum ALT.

Invention Summary:

Researchers at the University of Toledo have developed a novel method for detecting and diagnosing cholemia, a condition in which patients exhibit elevated bile acids in the blood.  By using whole blood, we developed a simple, sensitive, and accurate method for cholemia diagnosis by measuring erythrocytes resistance to osmotic fragility and this can be used to diagnose or screen for cholemia.

Application:

Diagnosis of any acute or chronic liver disease associated with cholemia

Advantages:

  • Cost-effective, simple, and non-invasive
  • Accurate and early detection of elevated bile acids in the blood
  • Applicable for any type of liver disease associated with cholemia
  • Whole blood can be employed; no need to isolate serum or plasma

IP Status:

Patent Pending

Website

http://utoledo.technologypublisher.com/technology/46947

Contact Information

TTO Home Page: http://utoledo.technologypublisher.com

Name: Lokesh Mohan

Title: Licensing Associate

Department: Technology Transfer

Email: lokeshwar.mohan@utoledo.edu

Phone: 419-530-6231